Antitrypanosomal Activity of 4-Aminobicyclo[2.2.2]octane Derivatives
Institute of Pharmaceutical Sciences, Karl-Franzens-University of Graz, Universitätsplatz 1, 8010 Graz, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2009, 77(7), 214; https://doi.org/10.3797/scipharm.oephg.21.PO-15
Submission received: 16 April 2009
/
Accepted: 16 April 2009
/
Published: 16 April 2009
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
Every year about half a million people are infected with Human African Trypanosomiasis (HAT) and more than 40.000 people die from this disease [1]. Infections with Trypanosoma brucei rhodesiense, which is the more virulent of the two causative organisms, can only be treated with two drugs, suramin and melarsoprol, which can cause severe side effects and which have to be administered by painful injections.[...]
Share and Cite
MDPI and ACS Style
WEIS, R.; FAIST, J.; SEEBACHER, W. Antitrypanosomal Activity of 4-Aminobicyclo[2.2.2]octane Derivatives. Sci. Pharm. 2009, 77, 214. https://doi.org/10.3797/scipharm.oephg.21.PO-15
AMA Style
WEIS R, FAIST J, SEEBACHER W. Antitrypanosomal Activity of 4-Aminobicyclo[2.2.2]octane Derivatives. Scientia Pharmaceutica. 2009; 77(Posters (PO)):214. https://doi.org/10.3797/scipharm.oephg.21.PO-15
Chicago/Turabian StyleWEIS, R., J. FAIST, and W. SEEBACHER. 2009. "Antitrypanosomal Activity of 4-Aminobicyclo[2.2.2]octane Derivatives" Scientia Pharmaceutica 77, Posters (PO): 214. https://doi.org/10.3797/scipharm.oephg.21.PO-15
